Glossary
-
Regulatory acronyms
- PBS - Pharmaceutical Benefits Scheme
- TGA- Therapeutic Goods Association
- PBAC - Pharmaceutical Benefits Advisory Committee
- MSAC - Medical Services Advisory Committee
- LSDP - Life Saving Drugs Program
- ATAGI - Australian Technical Advisory Group on Immunisation
- ESC - Economic Sub-Committee
- DUSC - Drug Utilisation Sub-Committee
- ARTG - Australian Register of Therapeutic Goods (ARTG)
-
Company acronyms
- AZ - AstraZeneca
- BI - Boehringer Ingelheim
- MSD - Merck Sharp Dohme
- BMS - Bristol Myers Squibb
-
Regulatory terms
- Cost-effectiveness - A medicine is considered cost-effective if the incremental benefits it offers over its main comparator(s) justify its incremental costs and harms.
- Cost-minimisation - An economic evaluation that evaluates the proposed medicine against the least costly comparator once it has been found no worse than its main comparator(s) in terms of effectiveness and toxicity.